Experimental combo for head and neck cancer shows promise, but trial halted early
Disease control
Terminated
This Phase 2 trial tested whether adding danvatirsen to the standard immunotherapy pembrolizumab helps people with recurrent or metastatic head and neck squamous cell carcinoma. About 69 adults with PD-L1 positive tumors were randomly assigned to receive the combination or pembro…
Phase: PHASE2 • Sponsor: Flamingo Therapeutics NV • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC